ConcertAI, Cambridge, MA 02138, USA.
Merck & Co., Inc., Rahway, NJ 07065, USA.
Future Oncol. 2023 Jun;19(18):1249-1259. doi: 10.2217/fon-2022-0963. Epub 2023 Jun 9.
Unfavorable prognostic factors among classical Hodgkin lymphoma (cHL) patients in the real-world setting have yet to be fully characterized. In this retrospective study using the ConcertAI Oncology Dataset, patient characteristics, unfavorable prognostic factors and treatment patterns were evaluated among patients diagnosed with cHL. Among 324 adult cHL patients diagnosed 2016-2021, 16.1% were classified as early favorable, 32.7% early unfavorable and 51.2% advanced disease. Early unfavorable patients were younger and had a larger nodal mass. The prognostic factor B symptoms was most frequently documented in early unfavorable patients (59.4%), followed by bulky disease (46.2%), >3 involved lymph node regions (31.1%), and erythrocyte sedimentation rate ≥50 (25.5%). In this analysis of real-world data, we found that nearly a third of newly diagnosed cHL patients had early unfavorable disease. Our analysis also showed differences in the proportion of patients for each unfavorable factor among patients with early-stage unfavorable cHL.
在真实世界环境中,经典型霍奇金淋巴瘤(cHL)患者的不良预后因素尚未得到充分描述。在这项使用 ConcertAI 肿瘤学数据集的回顾性研究中,评估了诊断为 cHL 的患者的患者特征、不良预后因素和治疗模式。在 2016 年至 2021 年间诊断出的 324 例成年 cHL 患者中,16.1%被归类为早期预后良好,32.7%为早期预后不良,51.2%为晚期疾病。早期预后不良的患者更年轻,且淋巴结肿块更大。不良预后因素 B 症状在早期预后不良的患者中最常被记录(59.4%),其次是大肿块(46.2%)、>3 个受累淋巴结区域(31.1%)和红细胞沉降率≥50(25.5%)。在这项真实世界数据的分析中,我们发现近三分之一的新诊断 cHL 患者患有早期预后不良疾病。我们的分析还显示了早期预后不良的 cHL 患者中每个不良因素的患者比例存在差异。